Humanwell medicine: Venlafaxine hydrochloride sustained release capsule was approved by FDA

The Melancholic Saga of Xiaomi in India

In January 2024, Xiaomi unveiled the Redmi Note 13 5G series in India, achieving an outstanding sales feat of nearly CNY 900 million within a mere two days. Expressing gratitude on Twitter, Xiaomi India thanked its consumers, hailing the series as "super smartphones that redefine excellence." The commitment echoed the promise to persist in delivering innovation and premium products to the Indian market.

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Haier Biomedical 'Smart Blood City Network' Lands in Brazil

Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.

D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline

EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.

2024 A-Share Market to Significantly Slow Down, Trending Towards HK or US Listings

According to IPO Zaozhidao, on April 8, Deloitte's China Capital Market Services Division released a review of the China mainland and Hong Kong IPO markets in the first quarter of 2024, as well as an outlook for the whole year.